<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748072</url>
  </required_header>
  <id_info>
    <org_study_id>DDAVP 01</org_study_id>
    <nct_id>NCT00748072</nct_id>
  </id_info>
  <brief_title>1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy</brief_title>
  <official_title>1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluated the effect of pre-biopsy treatment with 1-deamino-8-D-arginine
      (DDAVP) on the incidence of post-biopsy bleeding complications. This is a IV phase single
      centre, double blind, randomized controlled study in patients, with acute and chronic
      nephropathy, undergoing ultrasound-guided percutaneous renal biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renal biopsy is an essential procedure in the diagnosis of primary and secondary renal
      diseases. The technique has significantly improved over the past two decades because of the
      introduction of ultrasonography and automated-gun biopsy devices; however an accurate
      clinical, chemistry and renal ultrasound evaluation before and 24-hours post renal biopsy is
      necessary, because bleeding complications still occur in about 1/3 of our procedures, with
      major complications occurring in only 1.2% of patients. Of the data routinely collected for
      potential predictors of post-biopsy bleeding complications, only gender, age, and baseline
      partial thromboplastin time show a significant predictive value. The other variables
      investigated do not have any predictive value (Manno C et al, Kidney Int 2004). The majority
      of published studies, retrospective and non-randomized, on this topic have focused on the
      comparative performance of different renal biopsy techniques and types of needles, but no
      study has shown potential predictors of post-biopsy bleeding complications. On the other
      hand, the available studies have not shown any specific test to select patients with major
      risk of post-biopsy bleeding.

      The aim of this study is to evaluate the effect of pre-biopsy treatment with DDAVP or
      desmopressin on the incidence of post-biopsy bleeding complications.

      DDAVP is a synthetic derivative of the anti-diuretic hormone vasopressin; therefore, the
      administration of DDAVP is often accompanied by water retention, a drop in blood pressure and
      a secondary increase in heart rate. The haemostatic effect of DDAVP is related to an increase
      of vWF-factor VIII levels. DDAVP is the treatment of choice for most patients with von
      Willebrand (type I) disease and haemophilia A; moreover, the compound has been shown to be
      useful in a variety of inherited and acquired hemorrhagic conditions, including some
      congenital platelet function defects, chronic liver disease, uremia, and haemostatic defects
      induced by the therapeutic use of anti-thrombotic drugs such as aspirin and ticlopidine.
      Finally, DDAVP has been used as a haemostatic agent in patients undergoing surgery at major
      risk of bleeding. Disadvantages of DDAVP include reported rare thrombotic events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.</measure>
    <time_frame>Immediately post-biopsy and 24 hours post-biopsy.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients treated with 1 ml of s.c. saline solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDAVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDAVP</intervention_name>
    <description>0.3 mcg/kg subcutaneous</description>
    <arm_group_label>DDAVP</arm_group_label>
    <other_name>vasopressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>saline solution 1 ml subcutaneous</description>
    <arm_group_label>Saline solution</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females &gt; 16 and &lt; 80 years of age.

          2. Blood pressure &lt; 140/90 mmHg.

          3. Serum creatinine ≤ 1.5 mg/dl and/or creatinine clearance ≥ 60 ml/min.

          4. Bleeding time, prothrombin time, partial thromboplastin time, platelets and fibrinogen
             in the normal range.

        Exclusion Criteria:

          1. Biopsy of transplant kidney

          2. Poorly controlled hypertension

          3. Single kidney

          4. Renal cancer

          5. Hydro/pyonephrosis

          6. Renal size significantly reduced

          7. Severe obesity

          8. Coagulation disorder

          9. Serum creatinine &gt; 1.5 mg/dl and/or creatinine clearance &lt; 60 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Manno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center and Atelier for Epidemiological Studies, University of Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <results_first_submitted>December 30, 2014</results_first_submitted>
  <results_first_submitted_qc>December 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2015</results_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Carlo Manno</investigator_full_name>
    <investigator_title>Assistant Professor, Chair of Nephrology, Unit of Nephrology, University of Bari, Bari, Italy</investigator_title>
  </responsible_party>
  <keyword>Vasopressin</keyword>
  <keyword>bleeding</keyword>
  <keyword>biopsy</keyword>
  <keyword>ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetes Insipidus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled all patients with serum creatinine less than 1.5 mg/dL and/or estimated glomerular filtration rate greater than 60 mL/min/1.73m2 and normal coagulation parameters, undergoing ultrasound-guided biopsy of native kidney, in our Unit, from August 2008 to December 2009.</recruitment_details>
      <pre_assignment_details>The exclusion criteria were solitary kidney, kidney cancer, hydro/pyonephrosis, significantly reduced renal size at ultrasound image, severe obesity (body mass index &gt; 30), chronic kidney disease and acute kidney injury.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Saline Solution</title>
          <description>patients treated with 1 ml of s.c. saline solution</description>
        </group>
        <group group_id="P2">
          <title>DDAVP</title>
          <description>treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline Solution</title>
          <description>patients treated with 1 ml of s.c. saline solution</description>
        </group>
        <group group_id="B2">
          <title>DDAVP</title>
          <description>treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="15.0"/>
                    <measurement group_id="B2" value="39.5" spread="14.2"/>
                    <measurement group_id="B3" value="40.6" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.</title>
        <time_frame>Immediately post-biopsy and 24 hours post-biopsy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Solution</title>
            <description>patients treated with 1 ml of s.c. saline solution</description>
          </group>
          <group group_id="O2">
            <title>DDAVP</title>
            <description>treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size was calculated by the difference in post-biopsy bleeding complications. Since the presence of bleeding was demonstrated in about 30-40 % in our previous observational study, we hypothesized a reduction risk of 0.50 and an absolute reduction of risk from 0.40 to 0.20. The sample size of the study for a power of 0.80 and a significance level &lt;0.05 was calculated in 158 patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>heart rate was monitored every 6 hours after the biopsy for 24 hours</desc>
      <group_list>
        <group group_id="E1">
          <title>Saline Solution</title>
          <description>patients treated with 1 ml of s.c. saline solution</description>
        </group>
        <group group_id="E2">
          <title>DDAVP</title>
          <description>treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>mild increase of heart rate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A possible limitation of the study is the single-center design of the study, which could reduce the generalizability of our results and their external validity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Carlo Manno</name_or_title>
      <organization>University of Bari</organization>
      <phone>390805478878</phone>
      <email>c.manno@nephro.uniba.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

